Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up.

Abstract

Liver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate the prevalence of liver steatosis and fibrosis in IBD patients and to evaluate which factors influence changes in steatosis and fibrosis during follow-up. From June 2017 to February 2018, demographic and biochemical data was collected at baseline and after 6-12months. Measured by transient elastography (FibroScan), liver steatosis was defined as Controlled Attenuation Parameter (CAP) ≥248 and fibrosis as liver stiffness value (Emed) ≥7.3kPa. IBD disease activity was defined as C-reactive protein (CRP) ≥10mg/l and/or fecal calprotectin (FCP) ≥150μg/g. Univariate and multivariate regression analysis was performed; a p-value of ≤0.05 was considered significant. Eighty-two out of 112 patients were seen for follow-up; 56% were male. The mean age was 43 ± 16.0years, and mean BMI was 25.1 ± 4.7kg/m2. The prevalence of liver steatosis was 40% and of fibrosis was 20%. At baseline, 26 patients (32%) had an active episode of IBD. Using a multivariate analysis, disease activity at baseline was associated with an increase in liver steatosis (B = 37, 95% CI 4.31-69.35, p = 0.027) and liver fibrosis (B = 1.2, 95% CI 0.27-2.14, p = 0.016) during follow-up. This study confirms the relatively high prevalence of liver steatosis and fibrosis in IBD patients. We demonstrate that active IBD at baseline is associated with both an increase in liver steatosis and fibrosis during follow-up.